Evidence map›Paper›PMID 41926246›Full record

ArticleACS applied bio materials2026

Role of Anti-GD

Ozde Gokbayrak, Derya Ozel, Ayca Tuncel, Fatma Yurt, Hatice Efsun Kolatan, Aylin Erol, Efe Ozgur Serinan, Tekincan Aktas, Osman Yilmaz, Safiye Aktas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ozde GokbayrakDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.
Derya OzelDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Ayca TuncelDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Fatma YurtDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Hatice Efsun KolatanDepartment of Laboratory Animal Science, Institute of Health Sciences, Dokuz Eylul University, İzmir 35340, Turkey.
Aylin ErolDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.
Efe Ozgur SerinanDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.ORCID 0000-0002-3682-7590
Tekincan AktasDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.
Osman YilmazDepartment of Laboratory Animal Science, Institute of Health Sciences, Dokuz Eylul University, İzmir 35340, Turkey.
Safiye AktasDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey.ORCID 0000-0002-8765-0641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma (NB) is an embryonic tumor originating from the neural crest. The most well-defined genetic alteration in NB is the overexpression of the MYCN protein. PI3K/AKT/mTOR and AURORA signaling pathways play a role in MYCN stabilization, and abnormal activation of these pathways has been identified in NB. Nanoparticle (NP) drug delivery systems targeting tumor cells directly assist in the combined delivery of agents and reducing toxicity. In this study, the aim was to develop NPs that reduce the activity of mTOR and AURORA pathways, potentially decreasing MYCN protein enhancement and stability, by combining inhibitors and targeting them specifically to the tumor, and to demonstrate their effect in NB. Everolimus (EVER) and tozasertib (TOZA) encapsulated in NP and targeted with dinutuximab β (DTX-β). Experiments including viability, apoptosis, gene and protein expression determination were performed. DTX-β/EVER + TOZA@PEG-

Indexed as

Antineoplastic AgentsBiocompatible MaterialsNanoparticlesNeuroblastomaN-Myc Proto-Oncogene ProteinPolyethylene GlycolsAnimalsApoptosisCell ProliferationCell SurvivalDrug Screening Assays, AntitumorGangliosidesHumansMaterials TestingParticle SizeAntineoplastic AgentsBiocompatible Materialsganglioside, GD2GangliosidesMYCN protein, humanN-Myc Proto-Oncogene ProteinPolyethylene Glycolsanti-GD2AURORA inhibitorsMYCNneuroblastomatargeted drug delivery

Identifiers

PMID41926246
PMCPMC13102200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.